{"id":"ticagrelor-60mg","_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Ticagrelor 60mg","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T04:24:03.123347+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T04:24:18.565174+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T04:24:10.745770+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ticagrelor 60mg","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T04:24:11.574372+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Purinergic receptor P2Y12 negative allosteric modulator","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T04:24:12.146847+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL398435/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T04:24:12.051170+00:00"}},"_dailymed":null,"aiSummary":"Ticagrelor 60mg, marketed by Fundacin Biomedica Galicia Sur, is a well-established drug in its therapeutic class. The key composition patent expires in 2028, providing a strong barrier to generic competition until then. The primary risk is the lack of reported revenue data, which may affect investment and market valuation.","_scrapedAt":"2026-03-28T00:12:29.631Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T04:24:18.565439+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT06228456","phase":"PHASE4","title":"Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention","status":"RECRUITING","sponsor":"University of Florida","startDate":"2024-04-01","conditions":"Coronary Artery Disease","enrollment":50},{"nctId":"NCT04483583","phase":"PHASE4","title":"Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI","status":"COMPLETED","sponsor":"University of Florida","startDate":"2020-12-08","conditions":"Coronary Artery Disease","enrollment":81},{"nctId":"NCT03212287","phase":"","title":"Brilinta Clinical Experience Investigation","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-12-21","conditions":"Acute Coronary Syndrome, Old Myocardial Infarction","enrollment":663},{"nctId":"NCT03465644","phase":"PHASE4","title":"TAILored Versus COnventional AntithRombotic StratEgy IntenDed for Complex HIgh-Risk PCI","status":"COMPLETED","sponsor":"Duk-Woo Park, MD","startDate":"2019-02-12","conditions":"Coronary Stenoses","enrollment":2018},{"nctId":"NCT03729401","phase":"PHASE4","title":"Personalization of Long-Term Antiplatelet Therapy - RAPID EXTEND","status":"SUSPENDED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2019-08-22","conditions":"Coronary Artery Disease, Myocardial Infarction","enrollment":390},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT03119012","phase":"PHASE4","title":"P2Y12 Inhibitor Monotherapy Versus Extended DAPT in Patients Treated With Bioresorbable Scaffold","status":"TERMINATED","sponsor":"Samsung Medical Center","startDate":"2017-04-19","conditions":"Coronary Artery Disease, Stents, Atherosclerosis","enrollment":25},{"nctId":"NCT04307511","phase":"PHASE4","title":"A sTudy of Low Dose vs Standard Dose of tIcaGrelor on Platelet Function After intErvention for Acute Coronary syndRome in Diabetes Mellitus Patients","status":"RECRUITING","sponsor":"Shanghai Tong Ren Hospital","startDate":"2020-04-20","conditions":"Acute Coronary Syndrome Patients With Diabetes After PCI","enrollment":40},{"nctId":"NCT06283888","phase":"PHASE4","title":"CYP2C19 Genotype-Guided P2Y12 Receptor Inhibitor Selection After Complex Percutaneous Coronary Intervention","status":"RECRUITING","sponsor":"Zunyi Medical College","startDate":"2024-04-01","conditions":"ACS - Acute Coronary Syndrome, CYP2C19 Polymorphism","enrollment":1200},{"nctId":"NCT04255602","phase":"PHASE4","title":"A Study of Low and Standard-dose Ticagrelor After Intervention for ACS Patients","status":"UNKNOWN","sponsor":"Shanghai Tong Ren Hospital","startDate":"2020-02-19","conditions":"Acute Coronary Syndrome, Coronary Stent Implantation","enrollment":2120},{"nctId":"NCT05825391","phase":"NA","title":"Guided Antiplatelet Therapy in Interventional Treatment of Intracranial Aneurysms","status":"COMPLETED","sponsor":"Beijing Tiantan Hospital","startDate":"2023-05-04","conditions":"Intracranial Aneurysm","enrollment":590},{"nctId":"NCT04307485","phase":"PHASE4","title":"A Study of Low Dose vs Standard Ticagrelor on Platelet Function After Intervention for Acute Coronary Syndrome in Senior Patients","status":"UNKNOWN","sponsor":"Shanghai Tong Ren Hospital","startDate":"2020-03-10","conditions":"Senior Acute Coronary Syndrome Patients After PCI","enrollment":40},{"nctId":"NCT05903976","phase":"PHASE3","title":"De-escalating Antiplatelet Therapy to Assess Platelet Reactivity and Outcomes in High Bleeding Risk Patients With Recent ACS","status":"UNKNOWN","sponsor":"Azienda Ospedaliera Universitaria Policlinico \"G. Martino\"","startDate":"2023-06-12","conditions":"Dual Antiplatelet Therapy, Acute Coronary Syndrome, Coronary Artery Disease","enrollment":200},{"nctId":"NCT04006288","phase":"PHASE4","title":"Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease","status":"COMPLETED","sponsor":"University of Florida","startDate":"2019-09-06","conditions":"Coronary Artery Disease","enrollment":90},{"nctId":"NCT05831462","phase":"PHASE1, PHASE2","title":"De-escalation of Ticagrelor in Post PPCI","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2023-06-01","conditions":"Ticagrelor","enrollment":400},{"nctId":"NCT04718025","phase":"PHASE3","title":"Evaluation of Safety and Efficacy of Two Ticagrelor-based De-escalation Antiplatelet Strategies in Acute Coronary Syndrome","status":"UNKNOWN","sponsor":"Collegium Medicum w Bydgoszczy","startDate":"2022-02-07","conditions":"STEMI, NSTEMI, Unstable Angina","enrollment":4500},{"nctId":"NCT03129867","phase":"","title":"ADHerence of ticagrelOr in Real World Patients With aCute Coronary Syndrome","status":"COMPLETED","sponsor":"FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS","startDate":"2017-01-01","conditions":"Acute Coronary Syndrome","enrollment":480},{"nctId":"NCT05283356","phase":"PHASE4","title":"Single Antiplatelet Treatment With Ticagrelor or Aspirin After Transcatheter Aortic Valve Implantation","status":"UNKNOWN","sponsor":"Fundacin Biomedica Galicia Sur","startDate":"2022-01-21","conditions":"Severe Aortic Valve Stenosis, Aortic Valve Stenosis, Transcatheter Aortic Valve Replacement (TAVR)","enrollment":1206},{"nctId":"NCT04331145","phase":"PHASE4","title":"Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation","status":"COMPLETED","sponsor":"Andres Iñiguez Romo","startDate":"2020-06-23","conditions":"Symptomatic Aortic Stenosis","enrollment":40},{"nctId":"NCT05247385","phase":"PHASE4","title":"Platelet Aggregation and Adenosine Levels Among Patients Taking Ticagrelor or Prasugrel","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2017-03-20","conditions":"Coronary Artery Disease","enrollment":87},{"nctId":"NCT02539160","phase":"PHASE4","title":"Impact of Chronic Kidney Disease on the Effects of Ticagrelor in Patients With Diabetes and Coronary Artery Disease","status":"COMPLETED","sponsor":"University of Florida","startDate":"2016-02","conditions":"Coronary Artery Disease, Diabetes Mellitus","enrollment":101},{"nctId":"NCT05210595","phase":"PHASE4","title":"Optimal Dosage of Ticagrelor in Korean Patients With AMI","status":"UNKNOWN","sponsor":"Dong-A University","startDate":"2022-01-01","conditions":"Acute Myocardial Infarction, Ticagrelor","enrollment":120},{"nctId":"NCT04734353","phase":"PHASE4","title":"Prasugrel 5 mg vs. Ticagrelor 60 mg in CHIP (E5TION)","status":"UNKNOWN","sponsor":"Gyeongsang National University Hospital","startDate":"2020-01-15","conditions":"Coronary Artery Disease","enrollment":492},{"nctId":"NCT02618837","phase":"PHASE4","title":"Downstream Versus Upstream Strategy for the Administration of P2Y12 Receptor Blockers","status":"UNKNOWN","sponsor":"University of Padova","startDate":"2015-12-14","conditions":"Unstable Angina or Non ST Elevated Myocardial Infarction","enrollment":2520},{"nctId":"NCT04069234","phase":"PHASE3","title":"Study in Diabetes Mellitus Patients Without Prior Myocardial Infarction or Stroke Undergoing Elective Percutaneous Coronary Intervention.","status":"WITHDRAWN","sponsor":"Region Skane","startDate":"2019-09-15","conditions":"Diabetes Mellitus, Microvascular Coronary Artery Disease","enrollment":""},{"nctId":"NCT02376283","phase":"PHASE4","title":"P3AMI Antiplatelet Trial","status":"COMPLETED","sponsor":"The Royal Wolverhampton Hospitals NHS Trust","startDate":"2015-03-09","conditions":"Heart Attack","enrollment":87},{"nctId":"NCT02285751","phase":"PHASE2","title":"High \"on Treatment\" Platelet Reactivity in the Intensive Care Unit","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2012-11","conditions":"Critical Illness","enrollment":200},{"nctId":"NCT04060914","phase":"PHASE4","title":"LOwer Maintenance Dose TICagrelor in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention","status":"UNKNOWN","sponsor":"Beijing Anzhen Hospital","startDate":"2019-08-30","conditions":"Antiplatelet Therapy, Coronary Artery Disease, Percutaneous Coronary Intervention","enrollment":225},{"nctId":"NCT03224923","phase":"PHASE4","title":"A Novel Strategy For Personalized Long-Term Dual Antiplatelet Therapy (RAPID EXTEND PILOT STUDY)","status":"TERMINATED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2017-08-18","conditions":"Stable Coronary Syndrome, Percutaneous Coronary Intervention, Antiplatelet Therapy","enrollment":5},{"nctId":"NCT02487732","phase":"PHASE4","title":"Comparison of Ticagrelor vs. Prasugrel on Inflammation, Arterial Stiffness, Endothelial Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Coronary Stenting","status":"COMPLETED","sponsor":"Korea University Anam Hospital","startDate":"2015-07","conditions":"Acute Coronary Syndrome","enrollment":60},{"nctId":"NCT03881943","phase":"PHASE4","title":"Ticagrelor Monotherapy Compared to Aspirin Monotherapy in Patients With History of ACS","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2017-01","conditions":"Acute Coronary Syndrome","enrollment":200},{"nctId":"NCT03387826","phase":"PHASE4","title":"Low Dose Ticagrelor Versus Low Dose Prasugrel in Patients With Prior Myocardial Infarction","status":"COMPLETED","sponsor":"Attikon Hospital","startDate":"2018-01-11","conditions":"Myocardial Infarction, Diabetes Mellitus, Coronary Artery Disease","enrollment":20},{"nctId":"NCT01587651","phase":"PHASE4","title":"Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Subjects With Stable Coronary Artery Disease","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2012-03","conditions":"Coronary Artery Disease","enrollment":110},{"nctId":"NCT02663713","phase":"PHASE4","title":"A Randomized, Pharmacodynamic Comparison of Low Dose Ticagrelor to Clopidogrel in Patients With Prior Myocardial Infarction","status":"COMPLETED","sponsor":"University of Patras","startDate":"2017-01","conditions":"Myocardial Infarction, Diabetes Mellitus, Renal Disease","enrollment":20},{"nctId":"NCT02319941","phase":"PHASE2","title":"Comparison of Low-Dose, Standard-Dose Ticagrelor and Clopidogrel for Inhibition of Platelet Reactivity in Patients With Acute Coronary Syndromes","status":"COMPLETED","sponsor":"Seung-Jung Park","startDate":"2015-05-20","conditions":"Acute Coronary Syndrome","enrollment":65},{"nctId":"NCT02215993","phase":"PHASE4","title":"Sampling P2Y12 Receptor Inhibition With Prasugrel and Ticagrelor in Patients Submitted to Thrombolysis","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2013-07","conditions":"Acute Coronary Syndrome, Platelet Function","enrollment":50},{"nctId":"NCT01852214","phase":"NA","title":"Pharmacodynamic Effect of Prasugrel vs. Ticagrelor in Diabetes","status":"COMPLETED","sponsor":"University of Florida","startDate":"2013-02","conditions":"Diabetes Mellitus, Coronary Artery Disease","enrollment":50},{"nctId":"NCT02929888","phase":"PHASE2, PHASE3","title":"Study of Platelet Function After Administration of Aspirin Versus Lysine Acetylsalicylate in STEMI Patients","status":"UNKNOWN","sponsor":"Fundacion Investigacion Interhospitalaria Cardiovascular","startDate":"2016-10","conditions":"Acute Myocardial Infarction","enrollment":60},{"nctId":"NCT01700322","phase":"PHASE4","title":"Endothelium, Stenting, and Antiplatelet Therapy (EST) - Clopidogrel, Prasugrel, Ticagrelor Study","status":"COMPLETED","sponsor":"Johannes Gutenberg University Mainz","startDate":"2012-08","conditions":"Coronary Artery Disease","enrollment":126},{"nctId":"NCT02064985","phase":"PHASE4","title":"Ticagrelor China Pharmacokinetic/Pharmacodynamic Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-02","conditions":"Stable Coronary Heart Disease (CHD)","enrollment":61},{"nctId":"NCT01852175","phase":"NA","title":"Pharmacodynamic Effects of Prasugrel Compared With Ticagrelor in Patients With Coronary Artery Disease","status":"COMPLETED","sponsor":"University of Florida","startDate":"2012-01","conditions":"Coronary Artery Disease","enrollment":110},{"nctId":"NCT02108808","phase":"PHASE4","title":"Effect of Ticagrelor on Fractional Flow Reserve","status":"COMPLETED","sponsor":"University of Patras","startDate":"2014-04","conditions":"Fractional Flow Reserve","enrollment":76},{"nctId":"NCT01463163","phase":"PHASE4","title":"Ticagrelor in Comparison to Prasugrel for Early Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)","status":"COMPLETED","sponsor":"University of Patras","startDate":"2011-10","conditions":"Platelet Reactivity","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL398435"},"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Brillique","Brilinta 60 mg","High platelet reactivity patients","Brilique","Brillinta"],"phase":"marketed","status":"active","brandName":"Ticagrelor 60mg","genericName":"Ticagrelor 60mg","companyName":"Fundacin Biomedica Galicia Sur","companyId":"fundacin-biomedica-galicia-sur","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":6,"withResults":1},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T04:24:18.565439+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}